Assessment of the feed additive consisting of Saccharomyces cerevisiae CNCM I‐4407 (Actisaf® Sc 47) for rabbits for fattening and non‐food producing rabbits for the renewal of its authorisation (S. I. Lesaffre)

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of a preparation of dried cells of Saccharomyces cerevisiae CNCM I‐4407 (Actisaf® Sc 47) as a zootechnical additive for rabbits for fatte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EFSA journal 2024-07, Vol.22 (7), p.e8910-n/a
Hauptverfasser: Bampidis, Vasileios, Azimonti, Giovanna, Bastos, Maria de Lourdes, Christensen, Henrik, Dusemund, Birgit, Durjava, Mojca Fašmon, Kouba, Maryline, López‐Alonso, Marta, López Puente, Secundino, Marcon, Francesca, Mayo, Baltasar, Pechová, Alena, Petkova, Mariana, Ramos, Fernando, Villa, Roberto Edoardo, Woutersen, Ruud, Anguita, Montserrat, Bozzi Cionci, Nicole, Brozzi, Rosella, Innocenti, Matteo Lorenzo, Pettenati, Elisa, Revez, Joana, Tarrés‐Call, Jordi, Valeri, Piera, García‐Cazorla, Yolanda
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of a preparation of dried cells of Saccharomyces cerevisiae CNCM I‐4407 (Actisaf® Sc 47) as a zootechnical additive for rabbits for fattening and non‐food producing rabbits. The applicant provided evidence that the additive currently in the market complies with the existing terms of the authorisation. The Panel concluded that the additive remains safe for the target species, consumers and the environment. Regarding the safety for the user, the additive is not a skin or eye irritant. However, it should be considered as a potential skin and respiratory sensitiser, and any exposure through skin and respiratory tract is considered a risk. The present application for renewal of the authorisation did not include a proposal for amending or supplementing the conditions of the original authorisation that would have an impact on the efficacy of the additive. Therefore, there was no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.
ISSN:1831-4732
1831-4732
2314-9396
DOI:10.2903/j.efsa.2024.8910